Waiting For The Perfect Case: Why EMA Has Yet To Hold A Public Drug Safety Hearing
Executive Summary
The European Medicines Agency has yet to use the power it has to hold public hearings on marketed medicines that raise safety concerns. It says it will do so only when the time is right.
You may also be interested in...
Valproate In The Spotlight As EMA Releases Date For First Ever Public Hearing
The European Medicines Agency has released the date for its public hearing on valproate in which EU citizens will for the first time be given a voice in evaluating the safety of medicines on the market.
EMA Picks Valproate For First Public Hearing On Safety Of Marketed Medicines
The European Medicines Agency is re-examining the use of valproate in women to address ongoing safety concerns and will hold its first ever public hearing later this year to listen directly to the experience of EU patients with these medicines.
EMA Public Hearings On Marketed Medicines To Start Next Year
The European Medicines Agency is set to give EU citizens a voice in the safety evaluation of marketed medicines by holding its first public hearing next year, though no specific topic or date has been decided.